METHOD FOR PREDICTION OF DEVELOPING HAEMATOGENOUS METASTASES FOLLOWING COMBINED TREATMENT OF KIDNEY CANCER Russian patent published in 2014 - IPC G01N33/533 

FIELD: medicine.

SUBSTANCE: predicting developing haematogenous metastases following combined treatment of kidney cancer precedes determining the NF-kB p50, HIF-1α expression in the tumour tissue and the concentration of the vascular endothelial growth factor VEGF. Discriminant functions Y1, Y2 are calculated by equations: Y1=-3.2+0.026·X1+0.03·X2-0.02·X3+0.34·X4+0.3·X5; Y2=-33.3-0.01·X1+0.11-X2-1.2·X3+1.57·X4+1.8·X5, wherein X1 is the total proteasome activity ·10^-3 IU/mg of protein; X2 is the concentration of VEGF, pg/mg of protein; X3 is HIF-1 expression, standard unit/mg of protein in a well; X4 is NF-kB p50 expression, standard unit/mg of protein in a well. If observing Y1>Y2, the absence of the haematogenous metastases is predicted, while Y1<Y2 enables predicting developing the haematogenous metastases.

EFFECT: predicted developing kidney cancer, timely prescription of the most adequate therapeutic measures.

1 tbl, 2 ex